Related Experiment Video

Updated: Jun 6, 2025

Digital PCR for Quantifying Circulating MicroRNAs in Acute Myocardial Infarction and Cardiovascular Disease
04:41

Digital PCR for Quantifying Circulating MicroRNAs in Acute Myocardial Infarction and Cardiovascular Disease

Published on: July 3, 2018

8.1K

Inflammation-related markers in COVID-19 infection and ST-segment elevation myocardial infarction

Nart Z Baytuğan1, Hasan C Kandemir2, Aziz I Çelik3

  • 1Gebze State Hospital, Gebze, Kocaeli, Türkiye - nartzafer@hotmail.com.

Minerva Cardiology and Angiology
|November 29, 2024
PubMed

Insights

Inflammation markers like SII and PLR are associated with increased mortality risk in ST-segment elevation myocardial infarction (STEMI) patients, especially those with COVID-19. These markers can help predict outcomes in STEMI patients.

Area of Science:

  • Cardiology
  • Infectious Diseases
  • Inflammation Research

Background:

  • Investigating the link between inflammation markers and ST-segment elevation myocardial infarction (STEMI).
  • Assessing the impact of COVID-19 infection on STEMI outcomes.
  • Evaluating novel inflammation markers for risk stratification in cardiovascular events.

Purpose of the Study:

  • To explore the association between inflammation markers and STEMI.
  • To determine the predictive value of inflammation markers for mortality in STEMI patients, considering COVID-19 status.

Main Methods:

  • Observational, single-center, retrospective study of 149 STEMI patients (Jan 2020-Nov 2022).
  • Calculation of Systemic Immune-Inflammation Index (SII), Systemic Inflammation-Response Index (SIRI), Platelet-to-Lymphocyte Ratio (PLR), and Neutrophil-to-Lymphocyte Ratio (NLR).
  • Comparison of outcomes between COVID-19 positive and negative STEMI patient groups.

Main Results:

  • Overall in-hospital mortality was 12%.
  • Mortality was significantly higher in COVID-19 positive STEMI patients (24.3%) compared to COVID-19 negative STEMI patients (5.6%).
  • SII and PLR were identified as significant independent risk factors for mortality in STEMI patients.

Conclusions:

  • Systemic Immune-Inflammation Index (SII), Systemic Inflammation-Response Index (SIRI), Neutrophil-to-Lymphocyte Ratio (NLR), and Platelet-to-Lymphocyte Ratio (PLR) are effective inflammation markers.
  • These markers can predict mortality risk in ST-segment elevation myocardial infarction (STEMI) patients.
  • Inflammation markers may play a crucial role in managing STEMI, particularly in the context of viral infections like COVID-19.
Abstract

More Related Videos

Coronary Progenitor Cells and Soluble Biomarkers in Cardiovascular Prognosis after Coronary Angioplasty10:03

Coronary Progenitor Cells and Soluble Biomarkers in Cardiovascular Prognosis after Coronary Angioplasty

Published on: January 28, 2020

5.2K
A Research Method For Detecting Transient Myocardial Ischemia In Patients With Suspected Acute Coronary Syndrome Using Continuous ST-segment Analysis18:11

A Research Method For Detecting Transient Myocardial Ischemia In Patients With Suspected Acute Coronary Syndrome Using Continuous ST-segment Analysis

Published on: December 28, 2012

24.2K

Related Concept Videos

Blood Studies for Cardiovascular System I: Cardiac Biomarkers01:20

Blood Studies for Cardiovascular System I: Cardiac Biomarkers

Cardiac biomarkers are enzymes, proteins, and hormones released into the blood when cardiac cells are injured. They are powerful tools for triaging.
The essential diagnostic tools for detecting myocardial necrosis and monitoring individuals suspected of having acute coronary syndrome (ACS) include:
Troponins
Troponins, particularly cardiac troponins I and T, are the most precise and sensitive markers of myocardial injury. They are detectable within 4-6 hours of myocardial injury and remain...
103
Myocarditis II: Clinical features and Diagnostic Tests01:27

Myocarditis II: Clinical features and Diagnostic Tests

Myocarditis is an inflammation of the heart muscle. The symptoms vary widely, encompassing asymptomatic presentations to severe, acute manifestations.Clinical PresentationAsymptomatic cases: In some instances, myocarditis may be asymptomatic, with the infection resolving without intervention. These cases often go undetected unless discovered incidentally through diagnostic imaging or tests conducted for other reasons.General Early Symptoms: Early symptoms of myocarditis are non-specific and can...
2
Myocarditis I: Introduction01:21

Myocarditis I: Introduction

Myocarditis is inflammation of the myocardium, which is the muscular layer of the heart.EtiologyMyocarditis has a diverse etiology, including a wide range of infectious and non-infectious causes:Infectious CausesViral: Common viruses include Coxsackie A and B, adenovirus, parvovirus B19, enteroviruses, and influenza A.Bacterial: Examples include infections caused by Streptococcus, Staphylococcus, and Mycoplasma species.Rickettsial: Infections like Rocky Mountain spotted fever can result in...
2
Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers01:19

Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers

Cardiac biomarkers are critical in diagnosing, prognosing, and managing cardiovascular diseases. Routine measurement of specific biomarkers such as B-type natriuretic peptide (BNP), C-reactive protein (CRP), and homocysteine (Hcy) is common practice in clinical settings to evaluate heart function and predict cardiovascular events.
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
59
Myocarditis III: Medical Management01:14

Myocarditis III: Medical Management

Myocarditis: Comprehensive Medical ManagementMyocarditis, the heart muscle inflammation, requires a comprehensive medical management strategy that addresses the underlying cause, provides supportive care, manages symptoms, and reduces cardiac workload.Infections and Autoimmune CausesAdminister appropriate antimicrobial therapy when an infectious agent causes myocarditis. For instance, penicillin treats infections caused by Group A Streptococcus. In cases where autoimmune processes are...
2
Endocarditis II: Clinical features and Diagnostic Tests01:25

Endocarditis II: Clinical features and Diagnostic Tests

Endocarditis can present various clinical features depending on the causative organism and the patient's underlying health conditions. Initially, the clinical features of infective endocarditis develop gradually, presenting with nonspecific symptoms that can be easily mistaken for other illnesses.General SymptomsEarly symptoms of infective endocarditis are fever, chills, weakness, malaise, fatigue, and weight loss. These symptoms reflect the systemic nature of the infection and the body's...
2